Own CSL (ASX:CSL) shares? Here's why the government won't be extending the biotech's AstraZeneca vaccine contract

The government isn't looking beyond 2022 in the deal.

| More on:
Covid-19 vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is edging higher today and is currently trading hands at $298.49.

CSL shares are crawling northwards amid reports the Federal Government will not be renewing its contract with the biotech company to manufacture more AstraZeneca Plc (LON: AZN) COVID-19 vaccine doses.

Here's what we know.

Federal Government won't renew contract past 50 million doses

In a press conference yesterday, Federal Health Minister Greg Hunt advised that the Federal Government would not be renewing its contract with CSL to manufacture more AstraZeneca vaccines past the 53.8 million doses currently stipulated.

The blend of total volumes is made up of a 50 million dose production run in Australia, and a 3.8 million supply from overseas.

According to CSL, it has already manufactured 20 million doses under the agreement, with the remainder expected for completion next year.

Whilst the government's call may come as a surprise to some, minister Hunt explained it was "never contemplated that CSL would become a contract manufacturer", alluding to a position in long-term vaccine manufacturing for the government.

"They have other important global vaccine roles, as well as Australian vaccine…roles to be playing" Hunt said. As such, the government will be searching for alternative sources to manufacture its COVID-19 vaccine supply – whether that be domestically or not.

Hence nothing fundamental has changed for CSL at all, only that the government was never seeking to establish a long-term manufacturing relationship with CSL on the COVID-19 front.

Perhaps this is why the market has been easy on CSL shares today despite the news, as the biotech will still realise the full cash amount stipulated under the deal.

In a brief statement on its website, CSL quoted remarks made by chair Brian McNamee AO at its AGM, saying that the company is "pleased to say that the Australian Government and AstraZeneca trusted us as their partners to help the country respond to the emerging crisis through the most effective solution available: vaccination".

The rollout of AstraZeneca's SARS-CoV-2 vaccine label, Vaxzervria, has lagged its Pfizer competitor – Comirnaty – in Australia significantly, despite CSL's capacity to produce an additional 30 million doses.

For instance as of 10 October, of the roughly 30 million doses that had been administered in Australia, only around 41% of these were of the AstraZeneca label.

For reference, as of 14 October, 65.4% of the eligible population are double vaccinated against COVID-19 in Australia, with around 84% having at least one dose.

CSL share price snapshot

The CSL share price has had a difficult year to date, having posted a return of just 5.5% since January 1.

Despite this, it has slipped into the red by around 1% over the past 12 months.

These returns lag the S&P/ASX 200 index (ASX: XJO)'s return of around 19% in that time.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »